Monoclonal antibodies against infectious microbes: so long and too little!

Monoclonal antibodies against infectious microbes: so long and too little! Infect Disord Drug Targets. 2020 Mar 12;: Authors: Raj G, Priyadarshini R, Murugesan S, Adhimoolam M Abstract Monoclonal antibodies (mAbs) as alternatives or more often as complementary to the conventional antimicrobials are being developed for the management of infectious conditions for the past two decades. These pharmacotherapeutic strategies are inevitable as the burden of antimicrobial resistance is far-reaching in recent times. MAbs are part of the targeted pharmacotherapy armamentarium with high degree of specificity - hence, exert comparatively superior efficacy and tolerability than the conventional polyclonal antisera. So far, only five mAbs have been approved for the management of infectious states - since, the marketing authorization (1998) given to palivizumab (Synagis®) for the prophylaxis of lower respiratory tract disease caused by respiratory syncytial virus in pediatric patients. Ibalizumab-uiyk (Trogarzo™) used for the management of multidrug resistant HIV-1 infection not yielding to at least 10 antiretroviral drugs previously was approved recently. Among the three antibacterial mAbs, raxibacumab (ABthrax®/ Anthrin®) and obiltoxaximab (Anthim®) are indicated for the treatment and prophylaxis of inhalation anthrax due to Bacillus anthracis; bezlotoxumab (Zinplava®) is used to reduce the recurrence of Clostridium difficile infection. Th...
Source: Infectious Disorders Drug Targets - Category: Infectious Diseases Authors: Tags: Infect Disord Drug Targets Source Type: research